Premium
Clinical pharmacokinetic studies of tetra(meta‐hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths
Author(s) -
Braichotte Daniel,
Savary JeanFrançois,
Glanzmann Thomas,
Westermann Patrick,
Folli Silvio,
Wagnieres Georges,
Monnier Philippe,
Van Den Bergh Hubert
Publication year - 1995
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910630209
Subject(s) - photodynamic therapy , photosensitizer , chlorin , photodetection , fluorescence , pharmacokinetics , fluorescence spectroscopy , chemistry , photochemistry , cancer research , materials science , optoelectronics , medicine , optics , physics , organic chemistry , photodetector
To optimize photodynamic therapy (PDT) and photodetection of cancer with second‐generation photosensitizers, knowledge of important variables such as the uptake of the dye and the dye contrast between normal and tumoral tissue after injection is necessary. The pharmacokinetics of a second‐generation photosensitizer, tetra(meta‐hydroxyphenyl)chlorin (mTHPC), is presented. To study this in a clinical context, an apparatus based on fluorescence spectroscopy and a non‐invasive optical fiber probe has been used. The mTHPC fluorescence is induced at 2 excitation wavelengths (420 and 520 nm) with different penetration depth. The pharmacokinetics of mTHPC in patients with a squamous‐cell carcinoma in the oral cavity show a signal selectivity as high as 16 about 3 hr after i.v. injection for the more advanced carcinomas. The magnitude of this selectivity appears to correlate with the staging of the cancer, the more invasive tumors showing the highest selectivity. Results obtained at 420 and 520 nm show little difference. These pharmacokinetics can be used directly for optimizing photodetection with mTHPC. However, complementary information on the localization of the drug by fluorescence microscopy, and a correlation of this data with tumor necrosis efficacy, are needed to optimize PDT timing.